Wall Street is positive on TransMedics Group Inc (TMDX). On average, analysts give the stock a Strong Buy rating. The average price target is $21, which means analysts expect the stock to rise by 62.16% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 68, which is better than 68% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
Investors Observer combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With TransMedics Group Inc Stock Today?
TransMedics Group Inc (TMDX) stock has fallen -10.85% while the S&P 500 is unchanged 0% as of 9:39 AM on Tuesday, Sep 29. TMDX has fallen -$1.58 from the previous closing price of $14.53 on volume of 59,251 shares. Over the past year the S&P 500 has risen 12.59% while TMDX has fallen -45.47%. TMDX lost -$1.61 per share the over the last 12 months.
Click Here to get the full report on TransMedics Group Inc (TMDX) Stock.
